Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Zanubrutinib Plus Lenalidomide for Frail Elderly Patients With Newly Diagnosed Primary CNS Lymphoma: a Prospective, Single-arm, Phase II Clinical Study

NCT07839247 is registered in ClinicalTrials.gov with Xiaohui Ren as lead sponsor.

NCT NCT07839247
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07839247 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Zanubrutinib Plus Lenalidomide for Frail Elderly Patients With Newly Diagnosed Primary CNS Lymphoma: a Prospective, Single-arm, Phase II Clinical Study
Lead sponsor
Xiaohui Ren
Phase
Phase 2
Overall status
Recruiting
Start date
September 25, 2026
Completion date
August 1, 2029
Enrollment
33 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

frail elderly, lenalidomide, primary central nervous system lymphoma (pcnsl), zanubrutinib